At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 5, 2026 at 06:31 ET
Compass Pathways reported Q2 2026 results with a net loss of $1.88 per share, a wider loss vs $0.41 in Q2 2025, driven by non-cash warrant liability fair value adjustments. The core operational story remains on track: NDA rolling submission for COMP360 in TRD is underway with final submission expected in Q4, and commercial launch is targeted for H1 2027. The company holds $433M in cash, sufficient into 2028, but the GAAP loss miss vs consensus and the GAAP net loss widening are the headline financials for this pre-revenue biotech.
- Net loss of $253.8M ($1.88/share) for Q2 2026 vs $38.4M ($0.41/share) in Q2 2025, primarily due to a $205.6M non-cash loss from warrant liability fair value adjustments.
- Cash and cash equivalents of $433.3M as of June 30, 2026, compared to $149.6M at December 31, 2025.
- Rolling NDA submission for COMP360 in TRD is underway; final submission on track for Q4 2026.
- Commercial launch expected in first half of 2027, subject to FDA approval and DEA rescheduling.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access